"Despite recent advances in the treatment of NHL, iNHL generally remains
an incurable disease. As a result, there is a great unmet need in
patients with high-risk disease which is why the focus of this study has
the opportunity to make a difference," said
B-cell iNHL is expected to account for approximately 25 percent of 2017
newly diagnosed NHL cases in
ZUMA-5 is a single-arm, open-label, multi-center study in patients with iNHL whose disease has relapsed within two years of first line treatment, is refractory to second line or greater therapy or has relapsed at any point after transplant. The study will enroll approximately 50 patients. Additional details about this study can be found on ClinicalTrials.gov, using identifier NCT: 03105336.
About axicabtagene ciloleucel
Kite's lead product candidate, axicabtagene ciloleucel is an
investigational therapy in which a patient's T cells are engineered to
express a chimeric antigen receptor (CAR) to target the antigen CD19, a
protein expressed on the cell surface of B-cell lymphomas and leukemias,
and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel
is currently under review by the
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance the ZUMA-5 clinical trial and the estimated number of patients
with follicular lymphoma in the
1 Kochenderfer, J. N., et al. "B-Cell Depletion and
Remissions of Malignancy along with Cytokine-Associated Toxicity in a
Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor-Transduced T
Cells." Blood, vol. 119, no. 12,
News Provided by Acquire Media